Research communications in chemical pathology and pharmacology
-
Res. Commun. Chem. Pathol. Pharmacol. · Oct 1991
Comparative Study Clinical Trial Controlled Clinical TrialPlatelet alpha-2 adrenoreceptor activity pre-treatment and post-treatment in major depressive disorder with melancholia.
Changes in alpha-2 adrenoreceptor density and affinity during antidepressant treatment were studied using 3H-yohimbine binding to human platelet membranes. Baseline measurements were conducted in 21 patients diagnosed as having major depressive disorder with melancholia, and an equal number of age and sex matched normal controls. ⋯ Subjects participated for 6 weeks in a trial of placebo, adinazolam, or amitriptyline. Alpha-2 adrenoreceptor binding was not significantly changed from baseline following antidepressant treatment.